It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IBKR’s FA Score shows that 2 FA rating(s) are green whileRCKT’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IBKR’s TA Score shows that 7 TA indicator(s) are bullish while RCKT’s TA Score has 3 bullish TA indicator(s).
IBKR (@Investment Banks/Brokers) experienced а +3.81% price change this week, while RCKT (@Biotechnology) price change was -13.32% for the same time period.
The average weekly price growth across all stocks in the @Investment Banks/Brokers industry was +2.45%. For the same industry, the average monthly price growth was +14.20%, and the average quarterly price growth was +119.56%.
The average weekly price growth across all stocks in the @Biotechnology industry was -4.53%. For the same industry, the average monthly price growth was +10.36%, and the average quarterly price growth was -14.13%.
IBKR is expected to report earnings on Jul 22, 2025.
RCKT is expected to report earnings on Aug 11, 2025.
These banks specialize in underwriting (helping companies with debt financing or equity issuances), IPOs, facilitating mergers and other corporate reorganizations and acting as a broker or financial advisor for institutions. They might also trade securities on their own accounts. Investment banks potentially thrive on expanding its network of clients, since that could help them increase profits. Goldman Sachs, Morgan Stanley and CME Group Inc are some of the largest investment banking companies.
@Biotechnology (-4.53% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
IBKR | RCKT | IBKR / RCKT | |
Capitalization | 12B | 674M | 1,780% |
EBITDA | 6.6B | -247.48M | -2,668% |
Gain YTD | -0.229 | -49.801 | 0% |
P/E Ratio | 19.76 | N/A | - |
Revenue | 7.79B | 0 | - |
Total Cash | 3.75B | 372M | 1,009% |
Total Debt | 17M | 25.5M | 67% |
IBKR | RCKT | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 24 | 22 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 96 Overvalued | 30 Undervalued | |
PROFIT vs RISK RATING 1..100 | 25 | 100 | |
SMR RATING 1..100 | 46 | 93 | |
PRICE GROWTH RATING 1..100 | 43 | 57 | |
P/E GROWTH RATING 1..100 | 29 | 100 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RCKT's Valuation (30) in the Biotechnology industry is significantly better than the same rating for IBKR (96) in the Investment Banks Or Brokers industry. This means that RCKT’s stock grew significantly faster than IBKR’s over the last 12 months.
IBKR's Profit vs Risk Rating (25) in the Investment Banks Or Brokers industry is significantly better than the same rating for RCKT (100) in the Biotechnology industry. This means that IBKR’s stock grew significantly faster than RCKT’s over the last 12 months.
IBKR's SMR Rating (46) in the Investment Banks Or Brokers industry is somewhat better than the same rating for RCKT (93) in the Biotechnology industry. This means that IBKR’s stock grew somewhat faster than RCKT’s over the last 12 months.
IBKR's Price Growth Rating (43) in the Investment Banks Or Brokers industry is in the same range as RCKT (57) in the Biotechnology industry. This means that IBKR’s stock grew similarly to RCKT’s over the last 12 months.
IBKR's P/E Growth Rating (29) in the Investment Banks Or Brokers industry is significantly better than the same rating for RCKT (100) in the Biotechnology industry. This means that IBKR’s stock grew significantly faster than RCKT’s over the last 12 months.
IBKR | RCKT | |
---|---|---|
RSI ODDS (%) | 2 days ago53% | 2 days ago83% |
Stochastic ODDS (%) | 2 days ago63% | 2 days ago89% |
Momentum ODDS (%) | 2 days ago68% | 2 days ago83% |
MACD ODDS (%) | 2 days ago76% | 2 days ago71% |
TrendWeek ODDS (%) | 2 days ago73% | 2 days ago86% |
TrendMonth ODDS (%) | 2 days ago74% | 2 days ago77% |
Advances ODDS (%) | 6 days ago77% | 6 days ago80% |
Declines ODDS (%) | 2 days ago52% | 2 days ago84% |
BollingerBands ODDS (%) | 2 days ago71% | 2 days ago77% |
Aroon ODDS (%) | 2 days ago63% | 2 days ago90% |